Speakers

Geoffrey Gibney, MD

Co-Leader of the Melanoma Disease Group
The Lombardi Comprehensive Cancer Center and MedStar Cancer Network
Washington, DC

Dr. Gibney is a Co-Leader of the Melanoma Disease Group at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network in Washington, DC, and a member of the Developmental Therapeutics (Phase I) program.

Dr. Gibney is board certified in both internal medicine and medical oncology and has expertise in treating patients with advanced melanoma and non-melanoma skin cancers (such as basal cell carcinoma, squamous cell carcinoma and merkel cell carcinoma) as well as renal cell carcinoma. He is well recognized for his melanoma and renal cell carcinoma research.

Dr. Gibney’s past clinical research includes the study of adjuvant anti-PD-1 therapy in patients with high-risk resected melanoma, combination immunotherapies (such as ipilimumab plus the novel IDO1 inhibitor, epacadostat) to enhance the clinical benefit in advanced melanoma patients and combination BRAF targeted therapy to overcome drug resistance. He is currently involved in multiple clinical trials studying new immunotherapy strategies in melanoma and other malignancies and is involved in biomarker development for personalized therapeutic strategies in patients with advanced malignancies.

Back to top